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background:  Results of randomized trials have shown that ticagrelor and prasugrel improve outcomes compared with clopidogrel in 
acute coronary syndrome patients undergoing percutaneous coronary intervention (PCI). However their safety and efficacy as compared to 
clopidogrel in unselected patients with diabetes mellitus (DM) is unknown.
methods:  From January 2009 to December 2012 all patients affected by DM undergoing PCI in our center (Mount Sinai Hospital, New 
York City, New York) have been included in the study cohort and retrospectively analyzed. The study population was subdivided in 2 groups 
according to the antiplatelet medication at discharge, including: NAPD (ticagrelor or trasugrel) and clopidogrel. The primary objective was 
to compare the 1-year outcomes in terms of death, myocardial infarction (MI) and target vessel revascularization (TVR) between these 2 
study groups.
results:  Overall, 6249 patients affected by DM who underwent PCI were included in the study population. Of these, 5343 (86%) were 
discharged with clopidogrel and 906 (14%) with NAPD. Clopidogrel-treated patients were older with a higher prevalence of prior CABG and 
PAD. Conversely, NAPD use was more common in patients who underwent complex PCI (including bifurcation lesions, in-stent restenosis, 
longer lesions and left anterior descending artery as a target vessel). In unadjusted analyses, patients treated with clopidogrel had higher 
1-year all-cause mortality as compared to NAPD group (4% vs 1.9%; p = 0.003), while no differences were observed in 1-year MI and TVR. 
Conversely, following multivariable adjustment no differences in all-cause mortality (HR: 1.05; 95% CI: 0.7 - 1.5; p = 0.813), MI (HR: 0.8; 
95% CI: 0.5 - 1.2; p = 0.351) and TVR (HR: 1.1; 95% CI: 0.9 - 1.4; p = 0.134) at 1 year were observed between the 2 study groups.
Conclusion:  These results highlight important differences in the clinical and angiographic profiles of real-world patients with DM receiving 
clopidogrel versus NAPD. These competing influences may have mitigated any benefit from NAPD use previously observed in randomized 
cohorts.
